This study evaluated Seq ID No. 70 of a pan-RAS mRNA cancer vaccine (WO 2022/081764 A1; PCT/US 2021/054859), incorporating KRAS variants G12D, G13D, L19F, A59T, G60D, Q61H, K117N, and A146T, for its suitability in PDAC.<h4>Methods</h4>Immunoinformatic analyses were performed to predict cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL), and B-cell epitopes, which were assessed for antigenicity, allergenicity, and toxicity. The gene discussed is KRAS; the disease is cancer.